Posted On: 06/13/2016 7:09:34 AM
Post# of 1460
Looks like they are gonna be at AAIC 2016.
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
9:30am-10:30am Sun, Jul 24
https://ep70.eventpilotadmin.com/web/planner....AAIC16lite
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
P1-046
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
9:30am-10:30am Sun, Jul 24
https://ep70.eventpilotadmin.com/web/planner....AAIC16lite
(0)
(0)Scroll down for more posts ▼
